(IN BRIEF) A Phase III trial of Tezspire (tezepelumab) by AstraZeneca and Amgen has shown significant benefits for patients ...

in patients with chronic rhinosinusitis with nasal polyps (CRSwNP). The therapy met the co-primary endpoint of the WAYPOINT ...

November 08, 2024--(BUSINESS WIRE)--Positive high-level results from the Phase III WAYPOINT trial in patients with chronic rhinosinusitis with nasal polyps (CRSwNP ... significant and clinically ...

A phase 3 study has shown that when compared with placebo, Tezspire provided a statistically significant and clinically ...

Have you ever been frustrated by one side of your nose feeling completely blocked while the other is clear? As annoying as it ...

A deviated septum occurs when you have two different-sized nasal passageways which can cause one-sided congestion.

Amgen (AMGN) and AstraZeneca's (AZN) asthma therapy Tezspire hits main goals in the Phase 3 trial for chronic rhinosinusitis ...

often resulting from chronic inflammation. While these benign growths themselves are not harmful, they can lead to ...

Results from the Phase III WAYPOINT trial in patients with chronic rhinosinusitis with nasal polyps showed that AstraZeneca (AZN) and ...

Amgen (AMGN) and AstraZeneca (AZN) announced top-line results from the Phase 3 WAYPOINT trial in patients with chronic rhinosinusitis with ...

(Alliance News) - AstraZeneca PLC on Friday said it received positive results from a trial of Tezspire as a treatment for chronic rhinosinusitis with nasal polyps.